Lipid-modifying therapy and attainment of cholesterol goals in Europe: The Return on Expenditure Achieved for Lipid Therapy (REALITY) study

Current Medical Research and Opinion

Volumn 21, Issue 9, 2005, Pages 1389-1399

  Van Ganse, Eric ^a   Laforest, Laurent ^a   Alemao, Evo ^b   Davies, Glenn ^b   Gutkin, Stephen ^c   Yin, Don ^b  

^a CENTRE HOSPITALIER LYON SUD   (France)

^b MERCK RESEARCH LABORATORIES   (United States)

^c Rete Biomedical Communications Corp   (United States)

Author keywords

Coronary disease; Hydroxymethylglutaryl CoA reductase inhibitors; Hypercholesterolemia; Prevention and control; Statins

Indexed keywords

ATORVASTATIN; CERIVASTATIN; CHOLESTEROL; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; COHORT ANALYSIS; DRUG EFFICACY; DRUG POTENCY; DRUG TOLERABILITY; DYSLIPIDEMIA; EUROPE; FOLLOW UP; HUMAN; LIPID BLOOD LEVEL; MONOTHERAPY; PRACTICE GUIDELINE; PRESCRIPTION; RETROSPECTIVE STUDY; REVIEW; TREATMENT OUTCOME;

AGED; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; COHORT STUDIES; DATABASES; DRUG UTILIZATION REVIEW; EUROPE; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; ORGANIZATIONAL OBJECTIVES; PRACTICE GUIDELINES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 25444487260     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079905X59139     Document Type: Review

References (67)

1. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: Third Joint Task Force of European and other societies on cardiovascular disease prevention and clinical practice. Eur J Cardiovasc Prev Rehabil 2003;10(Suppl 1):S1-78
2. European Heart Network. Statistical data about cardiovascular disease in Europe. Available from http://www.ehnheart.org/files/ statistics%202005-092711A. pdf [Accessed 6 July 2005]
3. World Health Organization. World Health Report 2003. Available from http://www.who.int/entity/whr/2003/en/index.html [Accessed 6 July 2005]
4. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986;256:2823-8
5. Martin MJ, Hulley SB, Browner WS, et al. Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361 662 men. Lancet 1986;2:933-6
6. Stason WB. Costs and benefits of risk factor reduction for coronary heart disease: insights from screening and treatment of serum cholesterol. Am Heart J 1990;119:718-24
7. 4S Investigators. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9
8. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7
9. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001-9
10. LIPID Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998;339:1349-57
11. Collins R. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22
12. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58
13. Collins R, Armitage J, Parish S, et al. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004;363:757-67
14. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504
15. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004;291:1071-80
16. Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005;352:20-8
17. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005;352:29-38
18. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-22
19. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245-55
20. Canner PL, Furberg CD, Terrin ML, et al. Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol 2005;95:254-7
21. Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-16
22. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96
23. Rubins HB, Robbins SR, Collins D, et al. Gemfibrozil for secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs HDL Intervention Trial Study Group. N Engl J Med 1999;341:410-18
24. Adult Treatment Panel. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421
25. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39
26. International Atherosclerosis Society. Harmonized clinical guidelines on prevention of atherosclerotic vascular disease: executive summary. Available from http://www.athero.org/download/guidelines.pdf [Accessed 10 May 2005]
27. Frolkis JP, Pearce GL, Nambi V, et al. Statins do not meet expectations for lowering low-density lipoprotein cholesterol levels when used in clinical practice. Am J Med 2002;113:625-9
28. Sacks FM. Adherence to statin therapy: why aren't we doing better? Am J Med 2002;113:685-6
29. de Velasco JA, Cosin J, Lopez Sendon JL, et al. [Secondary prevention of myocardial infarction in Spain. The PREVERSE study]. Rev Esp Cardiol 1997;50:406-15
30. Velasco JA. After 4S, CARE and LIPID - is evidence-based medicine being practised? Atherosclerosis 1999;147(Suppl 1):S39-44
31. EUROASPIRE I and II Group. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet 2001;357:995-1001
32. EUROASPIRE Study Group. EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events. Eur Heart J 1997;18:1569-82
33. EUROASPIRE II Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001;22:554-72
34. Van Ganse E, Souchet T, Laforest L, et al. Effectiveness of lipid-lowering therapy. Br J Clin Pharmacol 2005;59:456-63
35. Van Ganse E, Souchet T, Laforest L, et al. Long-term achievement of therapeutic objectives of lipid-lowering agents in primary prevention patients and cardiovascular outcomes: an observational study. Atherosclerosis 2005 July 19 [Epub ahead of print]
36. Krobot KJ, Yin DD, Alemao E, et al. Real-world effectiveness of lipid-lowering therapy in male and female outpatients with coronary heart disease: relation to pre-treatment low-density lipoprotein-cholesterol, pre-treatment coronary heart disease risk, and other factors. Eur J Cardiovasc Prev Rehabil 2005;12:37-45
37. Rajagopalan S, Alemao E, Krobot K, et al. LDL-C goal attainment and cardiovascular hospitalization among CHD patients in Germany. Presented at European Atherosclerosis Society. Prague, Czech Republic (April 23-26, 2005)
38. Esposti ED, Melilli LE, Alemao E, et al. A population-based cross-sectional study on treatment patterns for hypercholesterolemia in Ravenna, Italy. Session P112. Presented at the 5th International Congress on Coronary Artery Disease - From Prevention to Intervention. Florence, Italy (October 19-22, 2003)
39. Esposti ED, Melilli LE, Alemao E, et al. Lipid testing and results in patients receiving lipid-lowering therapy in a northern region in Italy. Session P228. Presented at the 5th International Congress on Coronary Artery Disease - From Prevention to Intervention. Florence, Italy (October 19-22, 2003)
40. García Ruiz FJ, Ibanez AM, Pérez-Jiménez F, et al. and the REALITY Study Group. Current lipid management and low cholesterol goal attainment in common daily practice in Spain: the REALITY Study. PharmacoEconomics 2004;22(Suppl 3):1-14
41. Melilli LE, Alemao E, Yin, DD. Factors associated with cholesterol goal attainment in the United Kingdom: patient characteristics and management practices. Session 305 P2999. Presented at the European Society of Cardiology. Vienna, Austria (August 30-September 3, 2003)
42. Yin DD, Melilli LE, Alemao E. Trends in management of hypercholesterolemia in the United Kingdom: primary care practice from 1998 to 2001. Session 301 P633. Presented at the 5th International Congress on Coronary Artery Disease - From Prevention to Intervention. Florence, Italy (October 19-22, 2003)
43. Melilli LE, Alemao E, Yin DD. Persistency of lipid-lowering therapy in United Kingdom: primary care practices and associated factors. Session 305 P2998. Presented at the European Society of Cardiology. Vienna, Austria (August 30-September 3, 2003)
44. Ose L, Skjeldestad FE, Bakken IJ, et al. Current management of hyperlipidemia in Norway and factors associated with cholesterol goal attainment. Presented at European Atherosclerosis Society. Seville, Spain (April 17-20, 2004)
45. Lindgren P, Borgström F, Stålhammar J, et al. Association between achieving treatment goals for lipid-lowering and cardiovascular events in real clinical practice. Eur J Cardiovasc Prev Rehabil 2005 [in press]
46. Carlsson Å, Borgström F, Stålhammar J, et al. Costs of care for patients treated with lipid-lowering drugs. PharmacoEconomics 2004;22(Suppl 3):25-35
47. Goettsch WG, Yin DD, Alemao E, et al. Statins are less effective in common daily practice among patients with hypercholesterolemia: the REALITY-PHARMO study. Curr Med Res Opin 2004;20:1025-33
48. Mark L, Zámolyi K, Alemao E, et al. Cholesterol goal attainment among patients treated with lipid lowering drugs in Hungary. Session PCV32. Presented at EURO ISPOR Meeting 2004. Hamburg, Germany (October 24-26, 2004)
49. Darioli R, Alemao E, Davies G, et al. Lipid management and cholesterol goal attainment in Switzerland: the Swiss review of Return on Expenditure Achieved for Lipid Therapy (REALITY) study. Presented at European Atherosclerosis Society. Seville, Spain (April 17-20, 2004)
50. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502
51. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000;101:207-13
52. Cochran WG. Some methods for strengthening the common chisquare tests. Biometrics 1954;10:417-51
53. Armitage P. Tests for linear trends in proportions and frequencies. Biometrics 1955;11:375-85
54. Cramer JA. Effect of partial compliance on cardiovascular medication effectiveness. Heart 2002;88:203-6
55. Ito MK, Delucca GM, Aldridge MA. The relationship between low-density lipoprotein cholesterol goal attainment and prevention of coronary heart disease-related events. J Cardiovasc Pharmacol Ther 2001;6:129-35
56. Stein EA. Managing dyslipidemia in the high-risk patient. Am J Cardiol 2002;89:50C-7C
57. McDermott MM, Schmitt B, Wallner E. Impact of medication nonadherence on coronary heart disease outcomes. A critical review. Arch Intern Med 1997;157:1921-9
58. Pearson TA, Laurora I, Chu H, et al. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;160:459-67
59. Olson KL, Tsuyuki RT. Patients' achievement of cholesterol targets: a cross-sectional evaluation. Am J Prev Med 2003;25:339-42
60. Muls E, De Backer G, De Bacquer D, et al. LIPI-WATCH, a Belgian-Luxembourg survey on achievement of European Atherosclerosis Society lipid goals. Clin Drug Invest 2000;19:219-29
61. Eagle KA, Kline-Rogers E, Goodman SG, et al. Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study. Am J Med 2004;117:73-81
62. Roberts WC. The rule of 5 and the rule of 7 in lipid-lowering by statin drugs. Am J Cardiol 1997;80:106-7
63. Denke MA. Coadministration of multidrug therapy to achieve lipid goals. J Am Osteopath Assoc 2004;104:17-22
64. Pearson T, Denke M, McBride P, et al. Ezetimibe added to statin therapy reduces LDL-C and improves goal attainment in patients with hypercholesterolemia. Abstract presented at 2004 Scientific Session of the American College of Cardiology. New Orleans, La (March 7-10, 2004)
65. Kashyap ML, McGovern ME, Berra K, et al. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol 2002;89:672-8
66. Stein E, Stender S, Mata P, et al. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin. Am Heart J 2004;148:447-55
67. Gagné C, Bays HE, Weiss SR, et al. Efficiency and safety of ezetimibe added to on-going statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002;90:1084-91